

(19) World Intellectual Property Organization International Bureau



(43) International Publication Date  
12 February 2004 (12.02.2004)

PCT

(10) International Publication Number  
**WO 2004/012796 A1**

(51) International Patent Classification<sup>7</sup>: **A61M 5/142**

CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW.

(21) International Application Number:  
PCT/EP2003/007560

(22) International Filing Date: 12 July 2003 (12.07.2003)

(25) Filing Language: English

(84) **Designated States (regional):** ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(26) Publication Language: English

(30) Priority Data:  
02388048.7 31 July 2002 (31.07.2002) EP

(71) Applicant: NOVO NORDISK A/S [DK/DK]; Novo Allé, DK-2880 Bagsværd (DK).

**Published:**


— with international search report

(72) Inventor: SMEDEGAARD, Jørgen, K; Åløkkevej 20, DK-2720 Vanløse (DK).

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,

(54) Title: MEDICAL DELIVERY DEVICE



(57) **Abstract:** The present invention relates to a delivery device suitable for treatment of diseases or conditions in which a drug has to be applied through the skin of a patient. Thus, a delivery device is provided for delivering a liquid drug into the body of a patient, comprising a reservoir having, in a situation of use, an outlet, an amount of a liquid drug contained in the reservoir, expelling means for expelling the drug out of the reservoir through the outlet, and actuating means for actuating the expelling means. In accordance with the invention, the expelling means upon actuation is adapted for expelling the drug contained in the reservoir during a period of approximately 7-9 hours.

**MEDICAL DELIVERY DEVICE****FIELD OF THE INVENTION**

5 The present invention relates to a delivery device suitable for treatment of diseases or conditions in which a drug has to be applied through the skin of a patient. In a specific aspect, the invention is concerned with a delivery device and a method for the treatment of type 2 diabetes patients.

**10 BACKGROUND OF THE INVENTION**

Diabetes mellitus is the common name for at least 2 different diseases, one characterised by immune system mediated specific pancreatic beta cell destruction (insulin dependent diabetes mellitus (IDDM) or type 1 diabetes), and another characterised by decreased insulin sensitivity (insulin resistance) and a functional defect in beta cell function (non-insulin dependent diabetes mellitus (NIDDM) or type 2 diabetes). Whereas the insulin insensitivity does normally not progress, unless body weight increases, the beta cell function deteriorates over the years, as demonstrated in the UK Prospective Diabetes Study (UKPDS) which was a 20-year trial recruiting 5102 patients. The reason(s) for this remains not clear, but a stress situation of the beta cells may be involved. This deterioration can be detected as an overall increase in blood glucose levels, where the rise in night time blood glucose levels results in increased fasting blood glucose levels having an impact on the overall glycaemic control.

25 The principal treatment of type 1 diabetes is straight forward substitution of the missing insulin secretion, whereas treatment of type 2 is more complicated.

More specifically, in early stages of type 2 diabetes treatment a number of different types of drugs can be used, e.g. drugs which increase insulin sensitivity ("ciglitazones"), decrease hepatic glucose output (e.g. metformin), or reduce glucose uptake from the gut (alfa glucosidase inhibitors), as well as drugs which stimulate beta cell activity (e.g. sulfonylurea/meglitinides). All these drugs are used regularly, and very often in combination with each other. However, the above-described deterioration is reflected in the fact that beta cell stimulators will eventually fail to stimulate the cell, and the patient has to be treated with insulin, either as mono therapy, or in combination with oral medication in order to improve glucose control. Patients with type 2 diabetes also often have problems with dyslipidemia, hy-

pertension, and obesity, all of which are independent risk factors for developing macrovascular diseases. This means that patients with type 2 diabetes often receive a plethora of drugs.

5     Insulin treatment as such represents several problems for the patient as well as for the therapist: (i) Presently, insulin has to be injected in order to maintain its full biological potential. The insulin doses needed to control blood glucose excursions will depend on a number of factors, which will vary from day to day, e.g. size, type, and timing of food intake, stomach and gut function as well as exercise level. (ii) The blood glucose levels are also determined  
10    by several counter regulatory hormones, the most prominent being glucagon, cortisone, and epinephrine. (iii) Normal insulin secretion is characterised by pulsatile secretion into the portal vein and thereby directly into the liver, just as the secretion is regulated by both neural and humoral factors, as well as a number of nutrients are causing insulin secretion. The most prominent is glucose, but several amino acids, e.g. arginine, and also FFA will cause insulin  
15    secretion. (iv) Insulin secretion in connection with meals begins before the rise in blood glucose and the secretion in normal human beings is balanced to the amount of food intake. The primary function of insulin in connection with meals is to a) decrease hepatic glucose output, and b) increase glucose uptake in insulin sensitive tissues (muscle, adipose tissue). Fasting levels of plasma insulin are normally low at a constant level, and as the dose response  
20    curve for the muscle starts at a higher level than the curve for adipose tissue, the effect of insulin on glucose uptake in the muscle is minimal, whereas the antilipolytic effect of insulin is maintained.

25     To better understand the scope of the present invention, a general outline of the current treatment of diabetes will be given.

For type 1 diabetes in general, the state of the art treatment is based on multiple injections, where protracted (i.e. slow acting) insulins are administered once or twice daily, whereas short acting insulin is administered in connection with meals as a bolus injection. A major  
30    shortcoming of this treatment is the relative unreliability of the longer acting insulin preparation. The most commonly used insulin is the NPH which is characterized by a relatively rapid and pronounced start of action, and the plasma curve is clearly bell shaped meaning that the patients most of the time either get to much insulin or to little insulin. Newer insulin formulations, (insulin glargine, insulin detemir) are addressing this issue. A much more stable basal  
35    plasma insulin level is obtained by a relatively continuous subcutaneous insulin infusion us-

ing a pump. Moreover, the pump can also be used for administering bolus infusions through the same catheter. The effect on overall metabolic control, determined from HbA<sub>1c</sub> levels, is promising, and pump treatment in this group is able to produce glucose levels within the normal range. The outcome seems slightly better than data obtained with the multiple injection therapy, but both are capable of maintaining patients with good glycaemic control as indicated by HbA<sub>1c</sub> value in the normal range. A potential benefit when using a pump is the possibility of increasing the basal rate in the early morning hours, where the patient will need a little more insulin due to peaks of counter regulatory hormones. It will represent, however, a practical challenge, as the effect of the counter regulation is not constant and there will therefore be a risk of overdosing. On the other hand, it may turn out to be very useful in certain patients even if the insulin increase is not 100% optimal.

In type 2 diabetes the patients are normally started on oral treatment which is often maintained for too long a period, i.e. with a resulting long period of poor control due to decreasing beta cell function before the appropriate therapy with insulin treatment is started. There are several reasons for this as will be discussed in greater detail below. When eventually the decision to start insulin treatment in patients suffering from diabetes type 2 is taken, different treatment approaches can be followed, however, in recent studies it has been demonstrated that basal, night time insulin administration together with an orally taken drug (e.g. repaglinide or metformin) is superior to mono therapy with the oral drugs in advanced stages of the disease and the treatment is as efficacious as insulin mono therapy. Normally the patient will take an insulin injection (e.g. using NPH insulin) at bedtime and the oral medication during the day (often referred to as combination therapy). The advantages of this are that the patient does not have to take insulin injections during the day, do not have to balance food intake (e.g. size and time) with prandial insulin doses, and gain less weight as compared to full insulin treatment, see Yki-Järvinen H. et al. Comparison of insulin regimens in patients with non-insulin-dependent diabetes mellitus. N. Eng J. Med 1992; 327: 1426-1433, Puhakainen I, Taskinen M-J, Yki-Järvinen H. Comparison of acute daytime and nocturnal insulinization on diurnal glucose homeostasis in NIDDM. Diabetes Care 1994; 17: 805-809, and Kawamori R et al. Fasting plus prandial insulin supplements improve insulin secretory ability in NIDDM subjects. Diabetes Care, 1989; 12: 680-685. Later on many patients may advantageously be treated with a more complete insulin regimen consisting of twice daily injections of an insulin mixture, however there is a tendency towards also using bolus injections in selected patients, as many type 2 patients have severe problems in controlling the post prandial glucose levels.

35 In any case, the earlier the patient is made familiar with insulin injections as a necessary part

of the treatment, the better are the chances that the optimal treatment in any given situation can be used as early in the progress of the disease as possible thereby reducing the incidence of both the micro- and macro-vascular complications associated with long-time poor regulation of a type 2 diabetes.

5

As appears from the above, it would be beneficial if insulin injections could be used as an early supplement to oral drugs in the treatment of type 2 diabetes. However, experience has shown that this very often does not happen, the reasons being many and diverse and based upon concerns originating from both the medical practitioner, typically the patients general practitioner, and the patient.

10 From the patient's point of view injections are very cumbersome as the patient has to provide and store insulin in a proper way, to carefully remember to take the injections (one cannot count the remaining number of tablets as it is possible with oral treatment), and ultimately the patient has to inject insulin into the body using a needle. The latter action is perhaps the major patient related obstacle to the early introduction of insulin therapy as many people are afraid of needles, find the action both painful and unpleasant and, last but not least, they feel that needle treatment can only be associated with being "seriously ill", an association which is much weaker when taking oral drugs in the form of tablets which is just a "normal" occurrence like taking a tablet against headache or taking vitamins. Further, many patients have heard of and are afraid of hypoglycemia incidences associated with the use of insulin. Another important reason for patients refusing to start insulin treatment early is the fact that most patients at this point of time in their disease actually do not have any significant symptoms or suffer for any complications.

25

20 From the medical practitioner's point of view, patient compliance is a major issue as the "relative" need for insulin (i.e. the patient is not in urgent need for treatment with insulin) has to be held up against the risks associated with home treatment using insulin. More specifically, the medical practitioner will be concerned with the risk of overdosing (e.g. the patient taking too large doses and/or taking too many injections) and thereby the risk for hypoglycemic incidences. As many patients are middle-aged or elderly they are not used to, and perhaps do not understand, the kind of accuracy needed in insulin treatment, this in contrast to most diabetes type 1 patients which have started insulin treatment relatively early in life. Further, the insulin profiles achieved with a bedtime injection are not ideal, either resulting in a bell-shaped curve from NPH insulin, or a very flat curve from newly developed protracted in-

sulin types such as insulin glargine or insulin detemir, where a therapeutic level is build up slowly and where overdosing is a real issue, due to the very long acting profile.

## DISCLOSURE OF THE INVENTION

5

Having regard to the above-identified problems, it is an object of the present invention to provide a concept for the early insulin treatment of diabetes which is acceptable to both the medical practitioner and the patient, which is safe in use and which will overcome the existing prejudices against needle based insulin treatment. When in the following the term "insulin" is used, this denotes any insulin containing flowable drug or medicament formulation. Thus, the present invention is based on the realization that a device and method should be provided which is easy to use, which to a high degree minimizes the risks of overdosing, and which may help to break the patients' "emotional" barriers against insulin injections.

10 15 More specifically, the present invention is based on the concept of drug treatment performed substantially only during the approximately 8 hours during which a patient is at sleep (i.e. typically the night but could, indeed, be any 8 hours during a 24 hour day).

20 Thus, according to a first aspect of the invention, a delivery device is provided comprising a reservoir for insulin as well as means for allowing the contained insulin to be transferred to the body of the patient (user) during approximately 7-9 hours (e.g. 8 hours) or less in a controlled manner where after expelling is stopped, either due to the expelling means being stopped or due to the reservoir being empty.

25 30 The term "controlled" manner indicates that the insulin is delivered substantially in accordance with a predefined rate or profile. The transfer rate may be substantially constant, increasing or decreasing during the infusion period, or having any other desired profile just as the profile may be settable or programmable by the user or the attendant medical person.

35 The term "controlled" refers to a normal situation of use under normal circumstances, e.g. if the outlet from the reservoir is blocked for some reason, delivery of the preset amount of insulin may not take place or only in part.

The insulin is preferably infused subcutaneously through a small needle in fluid communication with a reservoir outlet means. The outlet means will normally be closed until connected

to a needle or corresponding device. The needle may be attached directly to the outlet opening or via a flexible catheter tubing. As the insulin is infused slowly over a relatively long period, a very fine needle can be used in contrast to the larger needle needed when the same amount of insulin has to be injected using a conventional syringe over a very short period,

5 e.g. 10 seconds. The term infusion is normally associated with delivery through a needle, however, when in the following the term infusion is used instead of the term delivery this is not intended to restrict the disclosure to any specific means for the delivery of a drug to the body of a patient.

10 In a preferred embodiment the infusion device is in the form of a "patch" comprising a lower surface provided with adhesive means and adapted to be arranged against and attached to a skin surface of the user, an infusion needle being arranged corresponding to the lower surface. In this way the needle is introduced subcutaneously as the infusion device is placed on the skin. As the needle is "hidden" on the lower surface of the device, the patient can mount

15 the device without having to look at the needle, just as the very fine needle assures that insertion is practically painless. In a further preferred embodiment, the infusion device is provided with the needle in a retracted, preferably hidden, position, such that the needle can be advanced after the device has been mounted on the skin. Advantageously, the needle insertion means are combined with actuation means adapted to initiate infusion of the contained

20 insulin.

This arrangement allows the skin-contacting surface to be placed on the skin (this surface being suitably provided with an adhesive coating or the device being provided with some other means of retaining the skin-contacting surface on the skin), and then a relative movement between the base member and the cartridge causes the penetration of the skin (and optionally, the actuation of the expelling means).

In accordance with an aspect of the present invention, the reservoir contains only a small amount of insulin corresponding to what is needed during the 8 hours the infusion device is adapted to be used, i.e. corresponding to the amount which may otherwise be injected at bedtime as a single injection.

The basal infusion level for a type 2 patient on early combination therapy is determined based on bodyweight and will be in the range of 5 to 50 units (IU), normally 10-40 IU, per 8 hours, depending on insulin sensitivity. As most of the patients are relatively resistant to insu-

lin, it is not imperative to titrate the dose meticulously as the patients still have a certain capability to counter regulate, and the doctor can have 3-5 night pumps at his disposal, either with the same infusion rate (ml/hour) and different insulin concentrations, or with the same insulin concentration but with different infusion rates.

5

Thus, in accordance with a second aspect of the present invention, an infusion device is provided comprising a reservoir with insulin as well as means for allowing the contained insulin to be transferred to the body of the patient in a controlled manner, wherein the reservoir contains an amount of insulin in the range from 5 to 50 IU, preferably from 10 to 40 IU, and the infusion device is adapted to transfer the insulin during a period of up to approximately 8 hours. The insulin may be fast acting for which a relatively constant infusion rate over approximately 8 hours may be used, or the insulin may be a slower acting type in which the insulin may be infused over a shorter period of time, just as slower acting insulin to a certain degree will "compensate" for any inaccuracies in the infusion rate provided by the infusion device.

10 To further "tailor" the insulin release to the body and the performance of the infusion device, a mixture of faster and slower acting insulins may be used.

15 More specifically, traditionally there are four types of insulin, based on how soon the insulin starts working (onset), when it works the hardest (peak time), and how long it lasts in the body (duration). However, each person responds to insulin in his or her own way so onset, peak time, and duration has to be given as ranges. Rapid-acting insulin (e.g. insulin Aspart) reaches the blood within 15 minutes after injection. It peaks 30 to 90 minutes later and may last as long as 5 hours. Short-acting (regular) insulin usually reaches the blood within 30 minutes after injection. It peaks 2 to 4 hours later and stays in the blood for about 4 to 8 hours. Intermediate-acting (NPH and lente) insulins reach the blood 2 to 6 hours after injection. They peak 4 to 14 hours later and stay in the blood for about 14 to 20 hours. Long-acting (ultralente) insulin takes 6 to 14 hours to start working. It has no peak or a very small peak 10 to 16 hours after injection. It stays in the blood between 20 and 24 hours or longer. Some insulins come mixed together, for example regular and NPH insulins, however, this is solely for the purpose of patients using pen or syringe devices for their injections; when using a pump device the object has traditionally been to "mimic" the pancreas for which reason rapid-acting insulin has been used in pumps.

In accordance with a third aspect of the invention a system is provided comprising at least two infusion devices each comprising a prefilled reservoir with insulin as well as means for allowing the contained insulin to be transferred to the body of the patient in a controlled manner, the reservoir containing from 5 to 50 IU, preferably from 10 to 40 IU, of insulin and the infusion devices being adapted for transferring the contained insulin during a period of up to approximately 8 hours, wherein each reservoir contains a different amount of insulin, thereby allowing a patient to be provided with the most suitable infusion device among the at least two infusion devices. For example, 4 different devices containing respectively 10, 20, 30 and 40 IU may be provided, however, a different number of devices containing different amounts of insulin may be provided.

In the above it is stated that the infusion device comprises means for allowing the contained insulin to be transferred to the body of the patient. These means may take any desirable form providing the desired function, but presently pump arrangements comprising a conveying arrangement connected to the reservoir (i.e. an outlet to be associated with needle infusion means) and including a pressure generating device for feeding the liquid contained in the reservoir by pressure or suction application from the reservoir to the body are preferred for transferring the insulin contained in the reservoir to the patient. In this respect a number of different pump principles may be utilized, e.g. osmotic pumps as known from for example US patents 4,340,048 and 4,552,561, piston pumps as known from for example US patent 5,858,001, membrane pumps as known from for example US patent 6,280,148, flow restrictor pumps (also known as bleeding hole pumps) as known from for example US patents 2,605,765 and 5,957,895, and gas generating pumps as known from for example US patent 5,527,288, which all in the last decades have been proposed for use in durable (refillable) and/or disposable (prefilled) drug infusion systems, however, until now only insulin infusion systems adapted to be used for considerably longer time than 8 hours have been proposed, thereby failing to provide a solution to the above-identified problems associated with the early treatment of diabetes type 2. The infusion device may be provided as a prefilled, entirely disposable device or as a disposable, prefilled portion comprising the reservoir, in combination with a durable control portion adapted to control the pump means which may be entirely or partly incorporated in the disposable portion. In the latter case the patient simply attaches a new disposable pump portion each evening. The control portion may be programmable, which option may or may not be accessible to the patient.

The present invention may also be implemented in the form of a multi-use pump unit which may be either prefilled or refillable, and which is specifically adapted to deliver a given profile of a drug during the specified period of approximately 8 hours after which the pump will automatically stop until it is restarted for a new infusion cycle. In case a user-fillable reservoir 5 is used, the delivery profile will basically be volume based whereas for a prefilled device the delivery profile may be based on activity (e.g. IU of insulin). Indeed, for a given drug having a given activity per unit of volume, a delivery profile based on activity can be calculated.

In the context of the present disclosure the term prefilled is used to characterize a device 10 which is supplied to the end-user in a prefilled condition. Preferably the drug reservoir of the device is adapted for not being refillable, e.g. the reservoir does not contain any user-accessible valves or self-sealing filling arrangements allowing for easy refilling. Further, the term refillable covers both the situation in which a reusable reservoir is refilled and the situation in which a prefilled reservoir (e.g. a cartridge) is inserted into a given delivery device.

15 Due to the limited amount of insulin infused during 8 hours, missing an infusion or having an incomplete infusion will not lead to a major deterioration in the glycaemic control of these patients, as spontaneous development of keto acidosis is not seen in patients with early type 2 diabetes, who has a residual endogenous insulin production which although not sufficient to 20 control blood glucose is sufficient to control ketone body metabolism, this in contrast to patients with type 1 diabetes. Moreover, the small total insulin content together with the relative insensitivity to insulin in type 2 patients makes the risk of developing nighttime hypoglycaemia a theoretical issue only. Thus, the infusion device may be of a relatively simple type dispensing with such features as an alarm and additional safety features, this in contrast to 25 (more sophisticated) pumps comprising a larger amount of insulin. Indeed, in case an infusion device comprising a durable control portion is preferred, many such advanced features may be readily incorporated, e.g. flow sensors, alarms, a display etc.

30 Referring back to the initially identified problems associated with the early introduction of insulin treatment, the above-proposed infusion devices will overcome one or more of these problems. More specifically, from the patient's point of view an infusion device is provided which in a preferred embodiment appears like a simple patch with a hardly recognizable needle having almost no resemblance to traditional insulin injection devices such as syringes 35 and pens, which is easy to use by simply attaching it to a skin surface before going to bed and removing it in the morning. From the medical practitioner's point of view, the risks of

overdosing due to the patients taking too large doses and/or taking too many injections are greatly reduced as the patient are provided with infusion devices comprising the prescribed amount of insulin just as the likelihood of applying two patches will be very low. In the same way the risks of underdosing due to the patients forgetting to take the injections are also reduced as it is very easy to check whether the patch has been attached or not.

5 Correspondingly, in accordance with a fourth aspect of the invention a method is provided for the treatment of a patient suffering from diabetes type 2, comprising the steps of: providing an infusion device adapted to infuse an amount of insulin to a patient, establishing at bedtime 10 a fluid communication between the infusion device and the body of the patient, infusing an amount of maximum 50 IU, preferably 10-40 IU, of insulin during a sleep period of approximately 8 hours, and removing the infusion device from the patient after approximately 8 hours.

15 Although a first object of the present invention has been to provide an improved treatment for patients suffering from diabetes type 2, the principles of the present invention may be used also in the treatment of other deceases in which a given drug necessarily or advantageously is infused over a prolonged period of timé, e.g. several hours.

20 Correspondingly, in accordance with a further aspect of the invention a device for delivering a liquid drug into the body of a patient is provided, comprising: a reservoir comprising, in a situation of use, an outlet, an amount of a drug contained in the reservoir, expelling means for expelling the drug out of the reservoir through the outlet, and actuating means for actuating the expelling means, wherein the expelling means upon actuation is adapted for expelling 25 a pre-determined amount of the drug contained in the reservoir during a period of approximately 7-9 hours in a controlled manner, after which period expelling is stopped, either due to the expelling means being stopped or due to the reservoir being empty. By the term "during" is indicated that the period of time between start of infusion and end of infusion corresponds to the specified timer interval, however, it does not imply that the infusion is constant 30 or that the infusion rate may not be zero for one or more intervals of time during that period of time, e.g. when using a pulsatile infusion pattern.

35 An example of a drug suitable for infusion using such a device is growth hormone (e.g. human or non-human, analogs, biologically active fragments and derivatives thereof, collectively called GH), in which infusion during a period of approximately 8 hours in many cases

would be more effective than one or more single injections during a period of 24 hours. Although the significance of this has been clear within the last two decades, most regimens of treatment have not reflected this knowledge. More specifically, GH secretion occurs in a pulsatile fashion and it is thought that changes in GH pulse amplitude are of great importance 5 for longitudinal growth. Although the pulses are distributed over the 24 hours of the day, the largest pulses are found during the period of sleep (i.e. typically during the night) just as relative more pulses are found during this period.

Correspondingly, in a preferred embodiment a delivery device comprises expelling means 10 providing a pulsatile delivery rate.

In accordance with a further aspect of the invention a method is provided for the treatment of a patient suffering from a decease, comprising the steps of: providing an delivery device adapted to infuse to a patient an amount of a drug beneficial for the treatment of the decease, establishing at bedtime a fluid communication between the delivery device and the body of the patient, delivering a therapeutic amount of the drug during a period of approximately 7-9 hours, and disconnecting the fluid communication between the delivery device and the body of the patient after approximately 7-9 hours. Preferably the period of sleep is used.

20 In respect of the delivery devices in accordance with the invention, these are specifically adapted for delivering a given amount of drug during the specified period of time, however, for the methods in accordance with the invention, the infusion device may also be in the form of a traditional programmable infusion pump as used for example in pump treatment of type 25 1 diabetes patients (this may be suitable in certain circumstances such as a trial phase or during hospitalization), however, to fully benefit from the concept of the present invention the infusion device is advantageously of the above-described type, i.e. a prefilled, disposable infusion device specifically adapted to infuse a contained amount of insulin during a maximum of approximately 8 hours.

30 In the context of the present invention the term expelling means is used as a general term covering situations in which drug is either forced from the reservoir by applying an external force or drawn or sucked from the reservoir using means arranged distally to the reservoir.

As used herein, the term "drug" is meant to encompass any drug-containing flowable medicine capable of being passed through a delivery means such as a hollow needle in a controlled manner, such as a liquid, solution, gel or fine suspension. Representative drugs include pharmaceuticals such as peptides, proteins, and hormones, biologically derived or active agents, hormonal and gene based agents, nutritional formulas and other substances in both solid (dispensed) or liquid form. In the description of the exemplary embodiments reference will be made to the use of insulin. Correspondingly, the term "subcutaneous" infusion is meant to encompass any method of transcutaneous delivery to a subject. Further, the term needle (when not otherwise specified) defines a piercing member adapted to penetrate the skin of a subject.

#### **BRIEF DESCRIPTION OF THE DRAWINGS**

In the following the invention will be further described with references to the drawings, wherein

fig. 1 shows a perspective view of an infusion device in an initial state,

fig. 2 shows a perspective view of the infusion device of fig. 1 in an actuated state,

fig. 3 shows a "horizontal" cross-sectional view of the infusion device of fig. 2,

fig. 4 shows a first "vertical" cross-sectional view of the infusion device of fig. 2,

fig. 5 shows a second "vertical" cross-sectional view of the infusion device of fig. 2,

fig. 6A shows in detail a flow restrictor,

fig. 6B shows in detail an infusion needle,

figs. 7A-7E shows different expelling means suitable for use with the invention, and

fig. 8A and 8B show embodiments of multi-use infusion pumps.

#### **35 DESCRIPTION OF A PREFERRED EMBODIMENT**

Fig. 1 shows a schematic representation of an embodiment of the invention. Correspondingly, the configuration of the different structures as well as their relative dimensions are intended to serve illustrative purposes only. When in the following terms as "upper", "lower", 5 "right" and "left" or similar relative expressions are used, these only refer to the appended figures and not to an actual situation of use. In the same way the terms "horizontal" and "vertical" refer to planes parallel with respectively perpendicular to a lower surface of the device to be described.

10 More specifically, fig. 1 shows an infusion device 1 comprising a housing 10 and therefrom protruding actuation button 20. The housing comprises an upper surface 2 and a lower surface 3 (not to be seen) adapted to be arranged against a skin surface of a user. The upper surface is provided with a transparent window 4 allowing the user to view a drug reservoir arranged within the housing. In fig. 2 the infusion device has been arranged against the skin 15 of a user and the actuation button has been pressed into the housing by the user thereby actuating the infusion device as will be explained in detail below.

With reference to fig. 3 the general construction of the infusion device will be described. The 20 housing comprises an upper wall 11, a lower planar base plate 12, side wall portions, an end wall 13 with an outer planar surface, and relative to the latter an opposed open end. Internally the housing comprises a first central wall 14 and a second oblique wall 15 in combination defining three compartments, a drive compartment 16, a reservoir compartment 17 and a needle compartment 18. The drive compartment forms a flat cylinder with an open proximal end and a substantially closed distal end. A piston 30 is slidably arranged in the cylinder dividing the drive compartment in a distal fluid compartment 31 filled with a viscous drive fluid 25 (e.g. silicon oil), and a proximal spring compartment 32. The actuation button 20 comprises a skirt portion 21 slidably received in the cylinder thereby closing the spring compartment. In the spring compartment are arranged two helical compression springs 33 acting on the piston, however, any compressible material or member providing a spring action or any other 30 means providing or generating a force (e.g. gas generating means or a liquid/gas mixture) acting on the piston may be utilized. The actuation button further comprises a wedge portion 22 to be received in the needle compartment.

As best seen in fig. 5 the reservoir compartment comprises a flexible drug reservoir 40 with 35 an insulin-containing drug formulation. The reservoir is preferably manufactured from a

transparent material allowing the user to view and control the drug through the window 4. In the initial state, i.e. before any drug has been expelled from the infusion device, the reservoir has a configuration substantially corresponding to the configuration of the reservoir compartment, thereby forming a neglectable cavity 19 (or dead-space) between the two components. In case an air filled dead space is not acceptable, the space may be filled with a fluid (for illustrative purposes the gap between the reservoir and the reservoir compartment is relatively large). As appears, the dead-space represents a cavity in a substantially fully collapsed state. Inside the drug reservoir is arranged a U-formed membrane element 41 formed from a self-sealing material and comprising upper and lower membrane portions 42, 43. In the end portion 13 is formed an outlet opening 34 from the fluid compartment and an inlet opening 44 to the reservoir compartment.

The infusion device further comprises a flow restrictor member 50 (see fig. 6) comprising a planer surface 51 in which a tortuous path 52 is formed between proximal and distal end portions 53, 54. The flow restrictor member 50 is bonded to the outer planar surface of the housing end portion with the proximal and distal end portions in register with the outlet 34 respectively the inlet openings 44. In this way a flow register is formed between the two openings. As appears, the resistance of the flow restrictor, the viscosity of the drive fluid and the force provided by the compressed springs will determine the rate at which the drive fluid will be forced through the flow restrictor to the drug compartment.

The infusion device further comprises a hollow infusion needle 60 as shown in fig. 7, comprising a distal pointed end 61 adapted to be introduced through a skin surface, a closed proximal end at which a needle wedge 62 is formed. In the body of the needle an opening 63 is formed in flow communication with interior of the needle. The proximal end of the needle is arranged in the needle compartment and with the needle body protruding through an opening 64 formed in the first wall 15 into the drug compartment and further into the reservoir. In the initial state (as supplied to the user and not shown in fig. 5) the needle penetrates the upper membrane portion 42 with the distal end 61 arranged between the upper and lower membrane portions 42, 43 inside the reservoir.

Next, with reference to figs. 4 and 5 actuation of the infusion device will be described. When the device has been positioned on a skin surface (preferably the lower surface comprises an adhesive coating) the user actuates the device by fully depressing the actuation button 20 until it locks in place in a recessed position (locking means arranged between the button and

the housing is not shown in the figs.) whereby simultaneously the springs 33 are compressed and the wedge portion 22 is moved into the needle compartment. The wedge portion comprises a lower oblique surface 23 in sliding contact with the needle wedge 62 whereby the wedge portion forces the needle downwardly as it is pressed into housing. By this action the 5 pointed distal needle end 61 penetrates the lower membrane portion 43 and is forced out through an opening 65 formed in the base portion. As the infusion device is attached to the skin surface of the user, the infusion needle is hereby introduced through the skin. When the needle is in its fully extended position, the needle opening 63 is positioned between the two membrane portions whereby a fluid communication is established from the drug reservoir to 10 the user. At the same time the drive fluid starts to be expelled from the fluid compartment 31 and through the flow restrictor to the cavity portion 19 where it gradually will compress the flexible reservoir and thereby force out the therein contained insulin-containing drug through the needle and into the user.

15 Initially air will be expelled from the needle just as air trapped in the flow restrictor and around the drug reservoir (if any) may result in an initial higher infusion rate, however, these effects will be neglectable.

20 In the shown embodiment the expelling means in form of springs 33 are "energized" during actuation of the device, however, to reduce the force needed to actuate the button 20 the spring means 33 may be pre-tensioned and the drive fluid 31 correspondingly pre-pressurized, whereby alone puncturing of the reservoir by the needle will actuate the expelling means and thereby start infusion.

25 In the above description of the preferred embodiments, the different structures providing the desired relations between the different components just as the means providing the described functionality for the different components (i.e. force generating means, flow restrictor, flexible reservoir etc.) have been described to a degree to which the concept of the present invention will be apparent to the skilled reader. The detailed construction and specification for 30 the different structures are considered the object of a normal design procedure performed by the skilled person along the lines set out in the present specification.

35 With reference to figs. 1-6 a specific type of a delivery device has been described, however, the expelling means and the reservoir may be of any type which would be suitable for arrangement within a drug delivery device.

In figs. 7A-7E examples of expelling means and reservoirs suitable for use with the present invention are shown schematically, however, these are merely examples. More specifically, fig. 7A shows a pump arrangement comprising a drug-containing cartridge 1010 forming a reservoir and having a distal closure member 1011 allowing a needle to be connected, and a piston 1015 slidingly arranged there within, a flexible toothed piston rod 1020, an electric motor 1030 which via a worm-gear arrangement 1031 drives the piston rod to expel drug from the cartridge, the motor being controlled by control means 1040 and the energy for the control means and the motor being provided by a battery 1050. Indeed, in alternative embodiments a straight piston rod may be used. The pump may be activated when the needle is inserted (by means not shown) or by separate user-actuatable means (not shown) after the needle has been inserted.

Fig. 7B shows a pump arrangement comprising a drug-containing cartridge 1110 having distal and proximal closure members 1111, 1112, and a piston 1115 slidingly arranged there within, gas generating means 1120 in fluid communication with the interior of the cartridge via conduit 1121 for driving the piston to expel drug from the cartridge, the gas generating means being controlled by control means 1140 and the energy for the control means and the gas generation being provided by a battery 1150. The pump may be activated as indicated above. A detailed disclosure of such gas generating means for a drug delivery device can be found in e.g. US patent 5,858,001.

Fig. 7C shows a pump arrangement comprising a drug-containing cartridge 1210 having distal and proximal closure members 1211, 1212, and a piston 1215 arranged there within, an osmotic engine 1220 in fluid communication with the interior of the cartridge via conduit 1221 for driving the piston to expel drug from the cartridge. The osmotic engine comprises a first rigid reservoir 1225 containing a salt-solution and a second collapsible reservoir 1226 containing water, the two reservoirs being separated by a semi-permeable membrane 1227. When supplied to the user, the fluid connection 1228 between the second reservoir and the membrane is closed by a user-severable membrane (e.g. a weak weld) which, when severed, will allow the osmotic process to start as water is drawn from the second reservoir through the membrane and into the first reservoir. The pump may be activated as indicated above. A detailed disclosure of the osmotic drive principle can be found in e.g. US patent 5,169,390.

Fig. 7D shows a pump arrangement substantially comprising to the one described with reference to figs. 1-6, comprising a drug-containing flexible reservoir 1310 arranged within a rigid fluid-filled secondary reservoir 1311 in fluid communication with a primary reservoir 1320 through a conduit 1330 comprising a flow restrictor 1331. The primary reservoir is in the form 5 of a cartridge with a moveable piston 1321 and contains a viscous drive fluid. A spring 1340 is arranged to act on the piston to drive fluid from the first to the second reservoir thereby expelling drug from the flexible reservoir when the latter is connected to an infusion needle (not shown). The flow rate will be determined by the pressure generated by the spring in the drive fluid, the viscosity of the drive fluid and the flow resistance in the flow restrictor (i.e. bleeding 10 hole principle). The pump may be activated by straining the spring or by releasing a pre-stressed spring, either when the needle is inserted (by means not shown) or by separate user-actuatable means (not shown). In an alternative configuration, the drug reservoir may be pressurized directly to expel the drug via a flow restrictor.

15 Fig. 7E shows a pump arrangement comprising a membrane pump 1430 having an outlet 1431 and control means 1440 for controlling the pump, the energy for the control means and the pump being provided by a battery 1450. The membrane pump is (in a situation of use) connected to a reservoir 1410 from which drug is sucked through the pump and expelled 20 through the outlet. The reservoir may be provided with venting means or it may be in the form of a flexible, collapsible reservoir whereby venting means can be dispensed with. The pump may be activated when the needle is inserted (by means not shown) or by separate user-actuatable means (not shown) after the inserter has been detached from the delivery device.

25 With reference to figs. 1-6 a delivery device adapted for single-use only was described, however, the present invention may also be implemented by a multi-use delivery device adapted for expelling a pre-determined amount of a drug during a period of approximately 7-9 hours in a controlled manner.

30 Correspondingly, fig. 8 shows an infusion pump 100 adapted for the delivery of a liquid during a period of 8 hours after which it automatically will stop. The pump comprises a housing 101 adapted to be arranged against the skin of the user (e.g. by adhesive or other means) or carried close to the skin (e.g. in a strap or belt) having a drug outlet 110, a user actuatable button 120 and a display 130. The pump is electronically controlled, however, the actual type 35 and configuration of the reservoir and expelling means may be of any suitable type. For ex-

ample, for a prefilled, disposable device any of the pump devices shown in figs. 7A, 7B or 7E would be suitable, whereas for a user-fillable pump the fig. 7A arrangement appears best suited.

5 In the shown embodiment the outlet is adapted for connection to a traditional skin-mountable infusion set 150 by means of a flexible conduit or tube 160. When the conduit has been primed (see below) and the needle or cannula 151 of the infusion set has been mounted subcutaneously, the user may start the infusion by actuation the start button 120 after which a pre-defined amount of drug will be expelled over the next 8 hours in accordance with a pre-defined delivery profile, e.g. constant or pulsatile infusion rate, after which the infusion set 10 and the pump is removed.

When using a relatively long conduit between the pump and the infusion needle or cannula, it is necessary to expel air contained in the conduit. After having connected the conduit to the 15 pump the user may do this manually by actuating a venting button (not shown) or the pump may be adapted to work only with proprietary infusion sets of known length in which case the venting may start automatically when the conduit is connected. When the infusion set has been vented it can be mounted on the patient and the pump can be started. This may be done manually by pressing the start button 120 or the pump may start automatically a given 20 amount of time after venting has taken place, e.g. 5 minutes. During operation it may be necessary to remove or replace the infusion set for which reason the pump can be manually stopped, e.g. by the user pressing the start button a relatively long time, e.g. 10 seconds. The pump may also be provided with automatic stop means capable of sensing a leak condition and sounding an alarm. In order to restart the pump cycle, the infusion pump advantageously 25 comprises means allowing the remaining portion of a cycle to be finished when an aborted pump cycle is started within a given amount of time, e.g. 1 hour. Otherwise a new cycle will have to be started or the remaining portion of the cycle will have to be dispensed with. To prevent that a new cycle is started just after the previous cycle has terminated, the pump may comprise timer means preventing restart of the pump before a pre-determined 30 time has lapsed, e.g. 1, 8 or 12 hours.

The display may be used to communicate different information to the user. For example, in a given pump cycle the display may indicate the remaining time, or after a cycle has been terminated it may be used to indicate the number of remaining cycles corresponding to the remaining amount of drug (calculated on the basis of either a prefilled or a user-filled reservoir). 35

If the remaining amount of drug does not suffice for a further full cycle, the display will indicate this just as an alarm (tactile, visual or audible) will be activated in case a further start is attempted.

5 In the fig. 8A embodiment a traditional infusion set is used, however, in an alternative configuration (see fig. 8B) the same type of pump may be used in combination with a needle which is connected directly to the pump, the combination providing a unitary device. The term "unitary" is used to define a device which can be handled and operated by the user as a single device, this in contrast to the above-described embodiment in which the pump 100 and the infusion set 150 is interconnected by a relatively long and flexible tube.

10

More specifically, the infusion pump 200 comprises a needle unit (or portion) 210 and a pump unit (or portion) 220. The needle unit comprises a pointed distal needle end adapted to penetrate the skin of the user, and an inlet in flow communication with the distal portion. The 15 pump unit comprises a reservoir adapted to contain a liquid drug and comprising an outlet means allowing the inlet of the needle unit to be arranged in fluid communication with the reservoir, and expelling means for, in a situation of use, expelling a drug out of the reservoir and through the skin of the subject via the pointed end. Further, the two units comprise mating coupling means 211, 221 allowing the needle unit to be releasably secured to the pump 20 unit thereby forming a rigid connection between the two units. Preferably, the needle unit comprises a lower surface, the pointed needle end being moveable between an initial position in which the first needle portion is retracted relative to the lower surface, and a second position in which the pointed end of the first needle portion projects relative to the lower surface. In an exemplary embodiment the lower surface is in the form of a mounting surface 25 adapted for application against the skin of the subject. In this way the needle can be inserted after the pump unit with the attached needle unit has been mounted on the patient, e.g. by adhesive means or by any other suitable means securing that the needle unit is firmly held in place. Advantageously, the connection between the reservoir and the distal needle end is short and narrow such that the venting procedure may be dispensed with due to the small 30 amount of entrapped air.

Although a mechanical design comprising no electronic means may be utilized for multi-use pumps as disclosed in figs. 8A and 8B, such pumps advantageously comprise an electronically controlled, battery-driven pump mechanism, e.g. of the types disclosed in figs. 7A and 35 7E.

As stated in the introductory portion, an object of the present invention is to provide a delivery device and a method which are safe and simple to use yet provide an effective medical treatment. Correspondingly, although an electronically controlled pump as disclosed in fig. 8  
5 may be programmable to provide a wide variety of infusion profiles suitable for a variety of patients, the programming means should not be accessible by the patient but only by e.g. the attending doctor. However, for a given type of drug and a given type of treatment, e.g. treatment of diabetes type 2, the programming may take place during manufacture only, whereby a number of different devices is supplied to the market, e.g. 4 different pumps supplying 10,  
10 15, 20 or 25 units of insulin during an 8 hour pump cycle.

Although the present disclosure has focused on the treatment of diabetes type 2, the infusion device of the invention may advantageously also be used in the treatment of diabetes type 1. For example, some long-acting (ultralente) insulin types designed to provide an insulin basal  
15 rate with a single daily injection will stay in the body for considerable longer than 24 hours. In order to provide the same "functionality" with a type of insulin which will act for a shorter period of time (thereby allowing the doctor to sooner "stop" the treatment) a type of insulin providing a basal rate for approximately 16 hours may be infused over 8 hours, thereby achieving a 24 hour basal rate with all the advantages associated with the infusion device of the  
20 present invention, yet providing the doctor with enhanced control of the treatment.

Although it is preferred that the delivery device of the invention is adapted to infuse the contained insulin over 8 hours, in certain applications the infusion may take place during a shorter period, e.g. in case the device is used as an automatic bolus device for infusing a slow acting  
25 type of insulin. In other application forms it may be desirable to infuse the contained insulin over e.g. approximately 2, 4 or 6 hours.

\*\*\*\*\*

**Documents cited in the application or considered relevant**

- Yki-Järvinen H. et al. Comparison of insulin regimens in patients with non-insulin-dependent diabetes mellitus. *N. Eng J. Med* 1992; 327: 1426-1433
- Puhakainen I, Taskinen M-J, Yki-Järvinen H. Comparison of acute daytime and nocturnal insulinization on diurnal glucose homeostasis in NIDDM. *Diabetes Care* 1994; 17: 805-809
- Kawamori R et al. Fasting plus prandial insulin supplements improve insulin secretory ability in NIDDM subjects. *Diabetes Care*, 1989; 12: 680-685
- US patent 4,340,048
- US patent 4,552,561
- US patent 5,858,001
- US patent 6,280,148
- US patent 2,605,765
- US patent 5,957,895
- US patent 5,527,288
- US patent 6,302,869
- US patent 6,074,369
- US patent 5,169,390

**CLAIMS**

1. A delivery device (1, 100), comprising:

- a reservoir (40) having outlet means, the reservoir being adapted to contain an amount of a liquid drug,
- expelling means (33, 41, 52) for in a situation of use expelling drug out of the reservoir through the outlet means,
- actuating means (20, 120) for actuating the expelling means,
- wherein the expelling means upon actuation performs a cycle of expelling a pre-determined amount of drug contained in the reservoir during a period of approximately 7-9 hours after which period expelling is stopped.

2. A delivery device as defined in claim 1, wherein the reservoir comprises a prefilled amount of drug.

15

3. A delivery device (100) as defined in claim 1 or 2, wherein the expelling means is adapted to perform a plurality of cycles, each cycle being initiated by actuation of the actuation means.

20

4. A delivery device as defined in claim 3, further comprising timing means preventing actuation of the expelling means for performing a further cycle before a preset period of time has lapsed since the previous cycle.

25

5. A delivery device (1) as defined in claim 1 or 2, wherein substantially the entire drug contained in the reservoir is expelled during a single cycle.

6. A delivery device as defined in any of claims 1-5, wherein the drug is insulin-containing.

30

7. A delivery device as defined in claim 5, wherein the reservoir comprises an amount of insulin in the range of 10-50 IU.

8. A delivery device as defined in claim any of the previous claims, further comprising a mounting surface adapted for application against the skin of a subject.

9. A delivery device as defined in claim 8, further comprising a delivery needle communicating in a situation of use with the interior of the reservoir and adapted to penetrate the skin of the patient, the delivery needle protruding from the mounting surface.

5 10. A delivery device as defined in claim 8, further comprising a delivery needle communicating in a situation of use with the interior of the reservoir and adapted to penetrate the skin of the patient, the delivery needle being moveable between a first position in which it is positioned within the device, and a second position in which it is protruding from the mounting surface.

10

11. A delivery device as defined in claim 10, further comprising needle advancing means for moving the needle from its first to its second position.

12. A delivery device as defined in claim 11, wherein the needle advancing means is 15 associated with the actuating means such that the action of advancing the needle will actuate the expelling means.

13. A delivery device as defined in any of claims 8-12, wherein the mounting surface comprises adhesive means allowing the device to be arranged against and attached to a skin 20 surface of the subject.

14. A delivery device as defined in any of the previous claims, comprising first and second portions adapted to releasably engage each other, the first portion comprises the reservoir and the second portion comprising control means, the expelling means being adapted to 25 be controlled by the control means.

15. A delivery device (200) as defined in any of the previous claims, comprising:  
- a first portion (210) comprising a pointed needle end adapted to penetrate the skin of a subject and inlet means in flow communication with the pointed needle end, and  
30 - a second portion (220) comprising a reservoir adapted to contain a liquid drug and having an outlet means allowing the inlet means to be arranged in fluid communication with the reservoir and expelling means for, in a situation of use, expelling a drug out of the reservoir and through the skin of the subject via the pointed needle end,  
- the first and second portions comprising mating coupling means (211, 221) allowing 35 the first and second portions to releasably engage each other to form a unitary device.

16. A delivery device as defined in claim 15, wherein the first portion comprises a lower surface, the pointed needle end being moveable between an initial position in which the pointed needle end is retracted relative to the lower surface, and a second position in which 5 the pointed end of the first needle portion projects relative to the lower surface.

17. A delivery device as defined in claim 16, wherein the lower surface is in the form of a mounting surface adapted for application against the skin of the subject.

10 18. A system comprising at least two delivery devices, each delivery device as defined in claim 2 and any claim dependent thereto, wherein each delivery device in its reservoir contains a different amount of insulin, thereby allowing a patient to be provided with the most suitable infusion device among the at least two infusion devices.

15 19. A method for the treatment of a patient suffering from a decease, comprising the steps of:

- providing a delivery device adapted to deliver an amount of a drug beneficial for the treatment of the decease,
- establishing at a given time a fluid communication between the delivery device and 20 the body of the patient,
- delivering a therapeutic amount of the drug during a period of approximately 7-9 hours, and
- disconnecting the fluid communication between the delivery device and the body of the patient after approximately 7-9 hours.

25

20. A method as defined in claim 19, wherein the fluid communication is provided by arranging the delivery device against a skin surface of the patient, and the fluid communication is disconnected by removing the infusion device from the patient.

30 21. A method as defined in claim 19 or 20, wherein the fluid communication is established at bedtime, the drug being infused substantially corresponding to a period of sleep.

22. A method as defined in any of claims 19-21, wherein the drug is insulin-containing.

23. A method as defined in any of claims 19-22, wherein a device (1) as defined in any of claims 1-12 is provided.

1/4

Fig. 1




Fig. 2





Fig. 3



2/4

Fig. 4




Fig. 5




Fig. 6A





Fig. 6B



3/4

Fig. 7A




Fig. 7B




Fig. 7C





Fig. 7D



4/4

Fig. 7E




Fig. 8A





Fig. 8B



# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/EP 03/07560

A. CLASSIFICATION OF SUBJECT MATTER  
IPC 7 A61M5/142

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)  
IPC 7 A61M

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category <sup>a</sup>	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5 858 001 A (GROSS JOSEPH ET AL) 12 January 1999 (1999-01-12) the whole document ---	1-18
X	US 2002/010423 A1 (GROSS JOSEPH ET AL) 24 January 2002 (2002-01-24) page 4, paragraph 88 -page 5, paragraph 96; figures 1-4 page 7, paragraphs 124-129 ---	1-18
X	US 5 672 167 A (HORRES JR C RUSSELL ET AL) 30 September 1997 (1997-09-30) column 8, line 22-34 column 12, line 38-44 column 11, line 29-37 figures 4A,4B,4C ---	1 -/-

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

<sup>a</sup> Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority, claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

\*&\* document member of the same patent family

Date of the actual completion of the international search

17 September 2003

Date of mailing of the international search report

23/10/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Ceccarelli, D

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/EP 03/07560

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 02 055128 A (BIOVALVE TECHNOLOGIES INC ; GONNELLI ROBERT R (US); LEVESQUE STEVEN) 18 July 2002 (2002-07-18) page 15, line 23 -page 16, line 2; figures 1,2 -----	1-18

**INTERNATIONAL SEARCH REPORT**International application No.  
PCT/EP 03/07560**Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)**

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1.  Claims Nos.: 19-23 because they relate to subject matter not required to be searched by this Authority, namely:  
Rule 39.1(iv) PCT - Method for treatment of the human or animal body by therapy
2.  Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3.  Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

**Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)**

This International Searching Authority found multiple inventions in this international application, as follows:

1.  As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2.  As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3.  As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4.  No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

**Remark on Protest**

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

## Information on patent family members

International Application No  
PCT/EP 03/07560

Patent document cited in search report		Publication date		Patent family member(s)	Publication date
US 5858001	A	12-01-1999		AT 214954 T AU 1808797 A CA 2238614 A1 DE 69620257 D1 DE 69620257 T2 EP 0902696 A1 WO 9721457 A1 JP 2000515394 T ZA 9610374 A	15-04-2002 03-07-1997 19-06-1997 02-05-2002 07-11-2002 24-03-1999 19-06-1997 21-11-2000 23-06-1997
US 2002010423	A1	24-01-2002		US 6500150 B1 AU 7786098 A EP 0989871 A1 WO 9857683 A1 JP 2002505601 T US 2001025168 A1 ZA 9805195 A	31-12-2002 04-01-1999 05-04-2000 23-12-1998 19-02-2002 27-09-2001 08-01-1999
US 5672167	A	30-09-1997		US 5257987 A AU 5585694 A WO 9511011 A1	02-11-1993 08-05-1995 27-04-1995
WO 02055128	A	18-07-2002		CA 2430590 A1 US 2002169416 A1 WO 02055128 A2	18-07-2002 14-11-2002 18-07-2002